Hussein D. Aoun MD, Abstract Co-Author: Nothing to Disclose

Peter John Littrup MD, Abstract Co-Author: Co-founder, Cryomedix, LLC Co-founder, CryoDynamics LLC Research support, HealthTronics, Inc

Sadeer Alzubaidi MD, Presenter: Nothing to Disclose

Barbara A. Adam BA, Abstract Co-Author: Nothing to Disclose

Yasmin Habibi MPH, Abstract Co-Author: Nothing to Disclose

We assessed the clinical and imaging outcomes of CT guided percutaneous cryotherapy for renal masses beyond 12 months, in relation to tumor size and location.

81 outpatient percutaneous CT fluoroscopic-guided cryoablations were performed on 81 masses in 69 patients. Percutaneously placed 2 cm esophageal dilatation balloons (N=4) or percutaneous local saline injection (N=25) acted as insulation barriers for adjacent bowel. Patients were followed by either CT or MRI at 1, 3, 6, 12, 18, 24 and 36 months and complications were graded according to Common Toxicity Criteria for Adverse Events Version 3.0 (CTCAE) of the National Cancer Institute.

All patients required minimal sedation during the procedure and most were discharged with minimal discomfort within 4-6 hours. Average tumor size was 2.8 cm (31 tumors > 3cm and 50 tumors < 3 cm).  No patients had long term complications or renal failure. Mean followup was 18 months and the longest follow up was 85 months. Forty-one ablated tumors had follow up > 24 month and 23 of which had follow up > 36 month. Average time to recurrence (local/regional) was 18.3 months. One patient had a single local tumor recurrence (1%) and five patients (6%) had regional disease recurrence. Regional recurrences were related to multicentric tumors (3) or the cryoprobe tract (2).

Percutaneous renal cryotherapy is a virtually painless, safe and technically feasible outpatient procedure with low recurrence rates beyond 12 months. Location and/or large tumors do not appear to preclude thorough treatment, or pose greater complication risks with appropriate probe placement and protective measures.

CT guided renal cryoablation is a minimally invasive, virtually painless procedure with excellent iceball visualization, low morbidity and low recurrence rates on long term followup.

Aoun, H, Littrup, P, Alzubaidi, S, Adam, B, Habibi, Y, CT-guided Percutaneous Cryoablation of Renal Tumors: Large Series with Minimum of Twelve Month Follow-up.  Radiological Society of North America 2010 Scientific Assembly and Annual Meeting, November 28 - December 3, 2010 ,Chicago IL. http://archive.rsna.org/2010/9013613.html